Table 2 Summary of the most significant associations of immunomodulatory ieQTLs with MPMs when compared to SPMs and/or disease-free controls, under the additive model (adjusted for age at pathological diagnosis, sex (male vs. female), and Ashkenazi Jewish status (yes vs. no)).
SNP | Gene | SNP Position (GRCh38.p12) | Alternate Allele in the Population | Alternate allele frequency MPM patients | Alternate allele frequency SPM patients | Alternate allele frequency disease free controls | MPM vs SPM | MPM vs disease-free controls* | ||
|---|---|---|---|---|---|---|---|---|---|---|
OR (95% C.I.) | p-value | OR (95% C.I.) | p-value | |||||||
rs2071304 | SPI1 | chr11:47350826 | G | 0.25 | 0.35 | 0.32 | 0.60 (0.45, 0.81) | 0.0007 | 0.59 (0.41, 0.83) | 0.0025 |
rs665241 | FYB | chr5:39266460 | C | 0.4 | 0.47 | 0.42 | 0.71 (0.55, 0.93) | 0.0111 | 0.89 (0.63, 1.13) | 0.2141 |
rs7720838 | PTGER4 | chr5:40486794 | G | 0.38 | 0.42 | 0.43 | 1.23 (0.94, 1.60) | 0.1313 | 0.66 (0.49, 0.89) | 0.0058 |
rs13331952 | CKLF | chr16:66549715 | C | 0.09 | 0.12 | 0.13 | 0.76 (0.50, 1.17) | 0.2177 | 0.59 (0.34, 0.93) | 0.0231 |
rs9895554 | SKAP1 | chr17:48046280 | C | 0.1 | 0.09 | 0.07 | 1.15 (0.74, 1.77) | 0.5355 | 1.69 (1.02, 2.63) | 0.0389 |
rs9863627 | PAK2 | chr3:196808928 | G | 0.09 | 0.1 | 0.15 | 1.15 (0.73, 1.82) | 0.5358 | 0.54 (0.33, 0.87) | 0.0111 |
rs2276645 | ZAP70 | chr2:97713589 | T | 0.31 | 0.34 | 0.44 | 0.95 (0.71, 1.28) | 0.7496 | 0.69 (0.49, 0.83) | 0.0083 |
